Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
3rd international conference of the Mediterranean Society of Tumor Marker Oncology (MESTMO), October 26-29, 1994, Athens, Greece.
3rd International Conference of the Mediterranean Society of Tumor Marker Oncology (MESTMO), October 26-29, 1994, Athens, Greece, 1994.. Unique Identifier : AIDSLINE ICDB/95614984 Anonymous; No affiliation given
Abstract:
The 3rd international conference of the Mediterranean Society of Tumor Marker Oncology, held October 26-29, 1994, in Athens, Greece, consisted of plenary lectures, symposia, and 10 sessions. The following plenary lectures were presented: new biological markers as a consequence of advances in molecular biology and pathology, molecular biology in clinical oncology, injury and carcinogenesis, PSA and the diagnosis and management of prostate cancer, clinical relevance of tumor proliferative activity on breast cancer, molecular approaches to the diagnosis and management of ovarian cancer, NK cells and certain interleukins--any use as prognostic markers?, multiple markers in rhabdomyosarcomas, circulating tumor markers in resectable non-small cell lung cancer, epitope prediction and confirmation for the human androgen receptor--generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy, anti-methionine cancer therapy--ethionine is synergistic with methionine depletion for inducing a therapeutic tumor-selective premitotic cell-cycle block, differentiation therapy of cancer--the role of inducers and markers, diagnostic and therapeutic value of intermediate filaments, and markers and modulation of drug resistance in human tumors. The symposia covered breast, urinary bladder, and GI tract cancers; chromosomal alterations; and oncogenes and oncosuppressor genes. The meeting sessions addressed these topics: serological tumor markers; flow cytometry, image analysis, in situ hybridization; immunohistochemistry; prognostic factors; molecular oncology; hormone receptors, growth factors; and AIDS-cancer, therapeutic progress. In addition, there were special lectures on (1) neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer using three different sets of patients and (2) the act homology/pleckstrin homology (AH/PH) domain of c-akt mediates the formation of act homodimers and contributes to the regulation of act activation induced by PDGF. Abstracts of presentations appear in the CANCERLIT data base with the following accession numbers: ICDB95614985 to ICDB95615066.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Bladder Neoplasms/DIAGNOSIS Breast Neoplasms/DIAGNOSIS Carcinoma, Non-Small-Cell Lung/BLOOD/DIAGNOSIS Cell Cycle Cell Differentiation Chromosome Abnormalities Drug Resistance Drug Synergism Female Flow Cytometry Gastrointestinal Neoplasms/DIAGNOSIS Human Immunohistochemistry In Situ Hybridization Killer Cells, Natural/IMMUNOLOGY Lung Neoplasms/BLOOD/DIAGNOSIS Male Methionine/ANTAGONISTS & INHIB *Neoplasms/DIAGNOSIS/GENETICS/PATHOLOGY/THERAPY Ovarian Neoplasms/DIAGNOSIS/THERAPY Platelet-Derived Growth Factor/PHYSIOLOGY Prognosis Prostate-Specific Antigen/ANALYSIS Prostatic Neoplasms/THERAPY Rhabdomyosarcoma/DIAGNOSIS *Tumor Markers, Biological MONOGRAPH
950630
M9561162
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
